¾«¶«Ó°Òµ

¾«¶«Ó°Òµ. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Company established its pharmaceutical marketing subsidiary, ¾«¶«Ó°ÒµSA/NV in Belgium. ¾«¶«Ó°ÒµSA/NV is owned by ¾«¶«Ó°ÒµEurope Limited (Headquarters: London, President: Yutaka Tsuchiya).

Serving as the regional sales hub for Benelux (Belgium, Netherlands and Luxembourg), which is the sixth largest market in the EU, ¾«¶«Ó°ÒµSA/NV will start marketing activities in all three Benelux countries hereafter with the focus on the anti-epileptic drugs Zonegran® and Inovelon®, as well as the non-opioid severe chronic pain agent Prialt®. In addition, ¾«¶«Ó°ÒµSA/NV plans to start co-promotion of its Alzheimer's disease treatment Aricept® in Belgium and Luxembourg with its co-promotion partner.

¾«¶«Ó°Òµplans further expansion of its business operations across Europe and will undertake “Independent Marketing” activities by using their own sales and marketing personnel, tailored for each county. ¾«¶«Ó°ÒµSA/NV is the Company's ninth marketing subsidiary in Europe, and brings the total number of countries where ¾«¶«Ó°Òµundertake sales and marketing operations through its own distribution channels to 17, including; the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands, and Luxembourg.

Through stable provision of Eisai's products, further enabled by the establishment of new subsidiaries and branches, ¾«¶«Ó°Òµis committed to increasing patient value and fulfilling the diverse needs of patients and their families throughout Europe.